Search filters

Filters
Clear All

Phase

  • 10
  • 15
  • 17
  • 11
  • 13
  • 70
  • 30
  • 3
  • 2
  • 65
  • 69
  • 1

Found 70 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
1. To determine the feasibility of integrating a PGx panel test in the EMR with a pharmacist PGx e-consult. 2. Determine the fidelity to genotype-guided pharmacotherapy recommendations. 3. To determine if PGx testing will improve the patient self-reported numeric pain scores 4. To determine if PGx testing will reduce MME …
99 years or below
All genders
Phase 2
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1  BRCA2 or PALB2 Mutation
18 years - 99 years
All genders
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …
 Study to Evaluate the Safety  Tolerability  and   Preliminary Efficacy of XmAb 20717 Alone or in Combination with Chemotherapy or Targeted Therapies in  Selected Subjects with Metastatic Castration-Resistant Prostate Cancer
18 years - 99 years
All genders
The primary purposes of this research study are to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies. Subjects are being asked to take part in this research study because they have metastatic castration resistant prostate cancer (mCRPC), a prostate cancer that has …
 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Interventional
This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.
99 years or below
All genders
Phase 3
The primary objective is to compare the PFS of patients randomized to MIRV vs. IC Chemo. Secondary objectives include: To compare the ORR of patients randomized to MIRV vs. IC Chemo, to compare OS of patients randomized to MIRV vs. IC Chemo, and to compare the primary patient-reported outcome (PRO) …
 A  Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy  as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive  Locally Advanced or Metastatic Non-small Cell Lung Cancer
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to try to find out if an experimental combination of an oral medication called osimertinib when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of non-small cell lung cancer (NSCLC). Eligible subjects will be adult subjects with …
99 years or below
All genders
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
 EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
18 years - 99 years
All genders
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it …
99 years or below
All genders
Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with acute myeloid leukemia with changed FLT3 gene where chemo is not an option due to old age/other conditions. Aims of this study: find suitable doses of gilteritinib, venetoclax and azacitidine as combined treatment; to learn how …